Pear Therapeutics

148 articles with Pear Therapeutics

• Pear Therapeutics Announces Process Exploring Strategic Alternatives

  3/17/2023

  Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics, announced that it is engaged in a process to explore strategic alternatives to maximize shareholder value.

• Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference

  2/27/2023

  Pear Therapeutics, Inc. today announced the Company will participate in the 43rd Annual Cowen Healthcare Conference being held March 6-8, 2023 in Boston.

• Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders

  1/26/2023

  Pear Therapeutics, Inc. announced today the expansion of its collaboration with BrightView Health, an addiction treatment provider that offers evidence-based, outpatient addiction treatment provider that offers evidence-based, outpatient addiction treatment programs.

• Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

  1/18/2023

  Pear Therapeutics Announces Inclusion of reSET ® and reSET-O ® on the January 2023 Florida Medicaid Preferred Drug List.

• Pear Therapeutics to Participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series

  1/17/2023

  Pear Therapeutics, Inc. today announced the company will participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series on Tuesday, January 24 at 11:00 a.m. ET.

• Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics

  1/10/2023

  Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics.

• Pear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery Across Multiple Locations and States

  1/4/2023

  Spero Health, one of the nation’s largest office-based outpatient opioid treatment providers for individuals in recovery, to expand patient access to Pear’s prescription digital therapeutics (PDTs) for the treatment of substance use disorder (SUD) and opioid use disorder (OUD).

• Pear Therapeutics Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using reSET® at AAAP

  12/15/2022

  Pear Therapeutics, Inc. today announced data from a real-world analysis of engagement, substance use, and retention patterns in patients diagnosed with substance use disorder who use alcohol and were treated with reSET.

• Pear Therapeutics Reports Third Quarter 2022 Results

  11/14/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022.

• Pear Therapeutics to Participate in the BTIG Digital Health Forum - November 10, 2022

  11/10/2022

  Pear Therapeutics, Inc. today announced management’s participation in the virtual BTIG Digital Health Forum being held on Monday, November 21.

• Pear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR Europe

  11/7/2022

  Pear Therapeutics, Inc. announced results from a retrospective analysis to evaluate the impact of Somryst® on healthcare resource use.

• Pear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference

  11/1/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR) today announced the company will participate in the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, California.

• Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022

  10/31/2022

  Pear Therapeutics, Inc. (the “Company”) (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of market on Monday, November 14, 2022.

• Pear Therapeutics to Participate in LifeSci Partners HealthTech Symposium

  9/13/2022

  Pear Therapeutics, Inc. today announced the company will participate in the LifeSci Partners HealthTech Symposium on September 20, 2022.

• Pear Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

  9/7/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference taking place September 12-14, 2022 in New York City.

• Pear Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference

  8/31/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi’s 17th Annual BioPharma Conference taking place September 7-8 in Boston, Massachusetts.

• Pear Therapeutics Reports Second Quarter 2022 Results

  8/11/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its second quarter ended June 30, 2022.

• Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®

  8/10/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR), today announced the publication of new results from a health economic analysis of real-world data to evaluate healthcare resource utilization, associated costs and insomnia severity for Somryst® (previously known as SHUTi in its prior incarnation), the only FDA-authorized PDT for the treatment of chronic insomnia.

• Pear Therapeutics and SelectHealth Announce Coverage to Provide Access to FDA-Authorized Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder

  8/8/2022

  Pear Therapeutics, Inc. and SelectHealth announced today that reSET-O®, the only FDA- authorized PDT to treat opioid use disorder (OUD), has been added as a covered benefit for SelectHealth’s members.

• Pear Therapeutics and Cove Behavioral Health to Provide Patients Access to Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder

  8/3/2022

  Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today that Cove Behavioral Health, Inc. (“Cove”) will provide access to Pear’s FDA-authorized PDT reSET-O® for the treatment of opioid use disorder (OUD).